These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 32876502)
1. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery. Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502 [TBL] [Abstract][Full Text] [Related]
2. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896 [TBL] [Abstract][Full Text] [Related]
3. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. Rukmangathen R; Yallamalli IM; Yalavarthi PR Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571 [No Abstract] [Full Text] [Related]
4. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain. Hanafy AS; Farid RM; ElGamal SS Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084 [TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106 [TBL] [Abstract][Full Text] [Related]
6. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia. Ahmad N; Ahmad R; Alam MA; Ahmad FJ Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380 [TBL] [Abstract][Full Text] [Related]
7. Ameliorative effect of alendronate against intracerebroventricular streptozotocin induced alteration in neurobehavioral, neuroinflammation and biochemical parameters with emphasis on Aβ and BACE-1. Zameer S; Kaundal M; Vohora D; Ali J; Kalam Najmi A; Akhtar M Neurotoxicology; 2019 Jan; 70():122-134. PubMed ID: 30481507 [TBL] [Abstract][Full Text] [Related]
8. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466 [TBL] [Abstract][Full Text] [Related]
9. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity. Elnaggar YS; Etman SM; Abdelmonsif DA; Abdallah OY J Pharm Sci; 2015 Oct; 104(10):3544-56. PubMed ID: 26147711 [TBL] [Abstract][Full Text] [Related]
10. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Bagre AP; Jain K; Jain NK Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363 [TBL] [Abstract][Full Text] [Related]
11. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Wang X; Chi N; Tang X Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400 [TBL] [Abstract][Full Text] [Related]
12. Brain-targeted Tet-1 peptide-PLGA nanoparticles for berberine delivery against STZ-induced Alzheimer's disease in a rat model: Alleviation of hippocampal synaptic dysfunction, Tau pathology, and amyloidogenesis. Saleh SR; Abd-Elmegied A; Aly Madhy S; Khattab SN; Sheta E; Elnozahy FY; Mehanna RA; Ghareeb DA; Abd-Elmonem NM Int J Pharm; 2024 Jun; 658():124218. PubMed ID: 38734273 [TBL] [Abstract][Full Text] [Related]
13. Development and optimization of in-situ gel containing chitosan nanoparticles for possible nose-to-brain delivery of vinpocetine. Hard SAAA; Shivakumar HN; Redhwan MAM Int J Biol Macromol; 2023 Dec; 253(Pt 6):127217. PubMed ID: 37793522 [TBL] [Abstract][Full Text] [Related]
14. Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia. Liu S; Ho PC J Pharm Pharmacol; 2017 Nov; 69(11):1495-1501. PubMed ID: 28809432 [TBL] [Abstract][Full Text] [Related]
15. Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress. Nabi B; Rehman S; Fazil M; Khan S; Baboota S; Ali J Drug Dev Ind Pharm; 2020 Mar; 46(3):471-483. PubMed ID: 32057274 [No Abstract] [Full Text] [Related]
16. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213 [TBL] [Abstract][Full Text] [Related]
17. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives. Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325 [TBL] [Abstract][Full Text] [Related]
18. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Mittal D; Md S; Hasan Q; Fazil M; Ali A; Baboota S; Ali J Drug Deliv; 2016; 23(1):130-9. PubMed ID: 24786489 [TBL] [Abstract][Full Text] [Related]
19. Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier. Gao X; Liu N; Wang Z; Gao J; Zhang H; Li M; Du Y; Gao X; Zheng A Molecules; 2021 Dec; 27(1):. PubMed ID: 35011436 [TBL] [Abstract][Full Text] [Related]
20. Cationic biopolymer functionalized nanoparticles encapsulating lutein to attenuate oxidative stress in effective treatment of Alzheimer's disease: A non-invasive approach. Dhas N; Mehta T Int J Pharm; 2020 Aug; 586():119553. PubMed ID: 32561306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]